The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Chemical modification of the adeno-associated virus capsid to improve gene delivery
Open accessAbstract
Bioconjugated AAV vectors, achieved by coupling of ligands on amino groups of the capsid, are of great interest for gene delivery. Chemical modifications can be used to enhance cell tropism and to decrease interactions with neutralizing antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“While in vivo data did not match the previous observation, neutralizing antibodies induction was greatly reduced in chemically modified capsid compared to standard capsid [117].”
From Risk mitigation of immunogenicity: a key to personalized retinal gene therapy (2021) · cites this paper as [117]
The cited source says what the claim attributes to it.
In the citing paper
“In vitro, using mouse hepatocytes, they showed increased transgene expression using chemically modified capsid compared to native AAV2 capsid.”
From Risk mitigation of immunogenicity: a key to personalized retinal gene therapy (2021) · cites this paper as [117]
The cited source says what the claim attributes to it.
In the citing paper
“Chemical modifications of the capsid can also impact the interaction of the AAV with host immunity as recently shown by Mével and his team.”
From Risk mitigation of immunogenicity: a key to personalized retinal gene therapy (2021) · cites this paper as [117]
In the citing paper
“Nacetylgalactosamine (GalNAc), a ligand targeting hepatocytes, was also conjugated to lysine residues of AAV capsids (138). Signi fi cant lower total antibodies and NAbs were observed in mice receiving GalNAc-AAV.”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [138]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Hinderer, C., Katz, N., Buza, E. L., Dyer, C., Goode, T., Bell, P., Richman, L. K., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.015 · Cited by 814
Engineering adeno-associated viruses for clinical gene therapy
Kotterman, M. A., & Schaffer, D. V. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3742 · Cited by 761
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Grimm, D., Lee, J. S., Wang, L., Desai, T., Akache, B., Storm, T. A., & Kay, M. A. (2008) · Journal of Virology · doi:10.1128/jvi.00254-08 · Cited by 696
Research works printed but not linked: 2
- Basner-Tschakarjan, 2014, Front. Immunol., 5, 350
- Herzog, 2004, Methods Mol. Biol., 246, 179
Cited by
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
“70 Conjugating the rAAV capsid with biotin-polyethylene glycol (PEG) 71 and N-acetylgalactosamine (GalNAc) 72 may help evade NAbs, although this is potentially at the cost of altered tissue tropism and reduced transduction ef fi ciency.”
BackgroundRecent progress in targeted delivery vectors based on biomimetic nanoparticles
Chen, L., Hong, W., Ren, W., Xu, T., Qian, Z., & He, Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00631-2 · Cited by 374
Manufacturing challenges and rational formulation development for AAV viral vectors
Srivastava, A., Mallela, K. M. G., Deorkar, N., & Brophy, G. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.03.024 · Cited by 269
Novel vectors and approaches for gene therapy in liver diseases
Maestro, S., Weber, N. D., Zabaleta, N., Aldabe, R., & González‐Aseguinolaza, G. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100300 · Cited by 159
Dogbey, D. M., Torres, V. E. S., Fajemisin, E. A., Mpondo, L., Ngwenya, T., Akinrinmade, O. A., Perriman, A. W., & Barth, S. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01362-3 · Cited by 105
Evading and overcoming AAV neutralization in gene therapy
Earley, J., Piletska, E. V., Ronzitti, G., & Piletsky, S. A. (2022) · Trends in biotechnology · doi:10.1016/j.tibtech.2022.11.006 · Cited by 93
Becker, J., Fakhiri, J., & Grimm, D. (2022) · Pathogens · doi:10.3390/pathogens11070756 · Cited by 91
“In the following, we will focus on the latter strategy as random conjugation methods often impacted vector titer or functionality [131,156].”
BackgroundNisanov, A. M., de Jesús, J. A. R., & Schaffer, D. V. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.056 · Cited by 89
“27 However, a general challenge for bioconjugation is the complexity of manufacturing, as additional production steps may reduce yields and increase reproducibility risk.”
Hacker, U. T., Bentler, M., Kaniowska, D., Morgan, M. A., & Büning, H. (2020) · Cancers · doi:10.3390/cancers12071889 · Cited by 79
“In this regard, Mevel and colleagues recently reported on isothiocyanate coupled ligands again using amino groups on the AAV capsid as a landing platform [55].”
BackgroundGlycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies
Rocamora, F., Peralta, A. G., Shin, S., Sorrentino, J., Wu, M. Y. M., Toth, E. A., Fuerst, T. R., & Lewis, N. E. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108206 · Cited by 67
Gross, D., Tedesco, N., Leborgne, C., & Ronzitti, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.857276 · Cited by 65
“Although the chemical alteration of AAV vectors may, in principle, extensively modify the capsid surface, only partial evasion of NAbs was reported so far (87).”
BackgroundBrown, D. A., Altermatt, M., Dobreva, T., Chen, S., Wang, A. Z., Thomson, M. W., & Gradinaru, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.730825 · Cited by 66
A versatile toolkit for overcoming AAV immunity
Li, X., Wei, X., Lin, J., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991832 · Cited by 57
“Nacetylgalactosamine (GalNAc), a ligand targeting hepatocytes, was also conjugated to lysine residues of AAV capsids (138).”
BackgroundClick-electrochemistry for the rapid labeling of virus, bacteria and cell surfaces
Depienne, S., Bouzelha, M., Courtois, E., Pavageau, K., Lalys, P.-A., Marchand, M., Álvarez‐Dorta, D., Nédellec, S., Marín-Fernández, L., Grandjean, C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40534-0 · Cited by 52
Self-citationThe curious case of AAV immunology
Keeler, A. M., Zhan, W., Ram, S., Fitzgerald, K. A., & Gao, G. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.037 · Cited by 52
Zhao, J., Yue, Y., Patel, A., Wasala, L. P., Karp, J. F., Zhang, K., Duan, D., & Lai, Y. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.08.006 · Cited by 42
Puzzo, F., Zhang, C., Gray, B. P., Zhang, F., Sullenger, B. A., & Kay, M. A. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.01.007 · Cited by 42
Słyk, Ż., Stachowiak, N., & Małecki, M. (2024) · Biomedicines · doi:10.3390/biomedicines12071523 · Cited by 44
Delivery of CRISPR/Cas9 system by AAV as vectors for gene therapy
Wang, Y., Jiang, H., Li, M., Xu, Z., Xu, H., Chen, Y., Chen, K., Zheng, W., Lin, W., Lin, Z., et al. (2024) · Gene · doi:10.1016/j.gene.2024.148733 · Cited by 44
Botto, C., Dalkara, D., & El-Amraoui, A. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.737632 · Cited by 31
“, 2017) and chemical modification of AAV capsids (Mével et al., 2019) have also provided variants valuable for gene delivery to the inner ear and retina.”
BackgroundTryptophan-specific modification and diversification of peptides and proteins
Kundu, S. K., Bandyopadhyay, A., & Sarkar, R. (2025) · Organic & Biomolecular Chemistry · doi:10.1039/d4ob02015d · Cited by 28
Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy
Rodríguez-Márquez, E., Meumann, N., & Büning, H. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1865303 · Cited by 30
“protrusion) by the random sequences [107].”
Ocular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions
Banou, L., Sarrafpour, S., Teng, C. C., & Liu, J. (2024) · The Yale Journal of Biology and Medicine · doi:10.59249/hwid7537 · Cited by 29
Lam, A. K., Frabutt, D. A., Li, L., & Xiao, W. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.124 · Cited by 28
“22”
Viral Nanoparticles‐Mediated Delivery of Therapeutic Cargo
Zanganeh, S., Doroudian, M., Nowzari, Z. R., Nasirmoghadas, P., Nahand, J. S., Sepehrpour, S., & Moghoofei, M. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300082 · Cited by 26
Chemical approaches to probe and engineer AAV vectors
Pham, Q. T., Glicksman, J., & Chatterjee, A. (2024) · Nanoscale · doi:10.1039/d4nr01300j · Cited by 25
Inner Ear Gene Therapy: An Overview from Bench to Bedside
Gadenstaetter, A. J., Krumpoeck, P. E., & Landegger, L. D. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00759-1 · Cited by 24
Immunogenicity of Novel AAV Capsids for Retinal Gene Therapy
Gehrke, M., Diedrichs‐Möhring, M., Bogedein, J., Büning, H., Michalakis, S., & Wildner, G. (2022) · Cells · doi:10.3390/cells11121881 · Cited by 20
“Optimized vectors should evade the host’s immune response while possessing enhanced tissue tropism and transduction efficiency [8,22].”
BackgroundChatterjee, J., Bandyopadhyay, A., Pattabiraman, M., & Sarkar, R. (2024) · Chemical Communications · doi:10.1039/d4cc01997k · Cited by 20
Leray, A., Lalys, P.-A., Varin, J., Bouzelha, M., Bourdon, A., Alvarez-Dorta, D., Pavageau, K., Depienne, S., Marchand, M., Mellet, A., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116148 · Cited by 17
Self-citationRisk mitigation of immunogenicity: a key to personalized retinal gene therapy
Varin, J., Morival, C., Maillard, N., Adjali, O., & Cronin, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312818 · Cited by 19
Self-citationMultivalent Targeting of the Asialoglycoprotein Receptor by Virus‐Like Particles
Hincapie, R., Bhattacharya, S., Baksh, M. M., Sanhueza, C., Echeverri, E. S., Kim, H., Paunovska, K., Podilapu, A. R., Xu, M., Dahlman, J. E., et al. (2023) · Small · doi:10.1002/smll.202304263 · Cited by 25
Emerging trends in virus and virus-like particle gene therapy delivery to the brain
Mandalawatta, H. P. P., Rajendra, K. C., Fairfax, K. A., & Hewitt, A. W. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102280 · Cited by 22
“57 Overall, capsid-modi fi cation techniques are of great interest and signi fi cantly broaden the scope of gene-based therapies. distinct transduction patterns within the nervous system.”
BackgroundErickson, S. B., Pham, Q. T., Cao, X., Glicksman, J., Kelemen, R. E., Shahraeini, S. S., Bodkin, S., Kiyam, Z., & Chatterjee, A. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00411 · Cited by 20
Emerging biotechnologies for engineering liver organoids
Zhao, J., Zhi, Y., Ren, H., Wang, J., & Zhao, Y. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.11.002 · Cited by 34
Macdonald, J., Marx, J., & Büning, H. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.169 · Cited by 18
“163 Thus, it appears that covering the capsid surface with targeting moieties not only influences AAV tropism but may also hinders a host immune response to the AAV capsid.”
Mannose-coupled AAV2: A second-generation AAV vector for increased retinal gene therapy efficiency
Mével, M., Pichard, V., Bouzelha, M., Álvarez‐Dorta, D., Lalys, P.-A., Provost, N., Allais, M., Mendes, A., Landagaray, E., Ducloyer, J., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101187 · Cited by 18
“Bioconjugation of the mannose ligands 5 and 7 to the rAAV2 capsid surface was performed using an optimized version of a previously described protocol.(12) Chemical coupling was achieved by nucleophilic addition of the amino group of the capsid proteins to the reactive isothiocyanate motif of the ligand compound 5, yie…”
BackgroundMethodResultInfluentialSelf-citationIntravitreal air tamponade after AAV2 subretinal injection modifies retinal EGFP distribution
Ducloyer, J., Pichard, V., Mével, M., Galy, A. H. M., Lefevre, G. M., Brument, N., Álvarez‐Dorta, D., Deniaud, D., Mendes-Madeira, A., Libeau, L., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.02.006 · Cited by 16
Self-citationElectrical Characterization and Analysis of Single Cells and Related Applications
Zhu, W., Wang, J., Luo, H., Liu, S., Luo, B., Liu, S., Li, C., & Li, C. (2023) · Biosensors · doi:10.3390/bios13100907 · Cited by 15
“However, rAAV has poor target specificity and a relatively low therapeutic index for systemic gene therapy [77], and optimized AAV gene delivery vectors that can be used for cell-type-specific delivery are urgently needed [78].”
BackgroundWang, S., & Xiao, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052213 · Cited by 20
“To decrease the host immune response, conjugating the rAAV capsid with bio-tin-polyethylene glycol (PEG) and N-acetylgalactosamine (GalNAc) may help evade Nabs, leading to longer and more efficient transgene expression [93–95].”
Chemical modification of AAV9 capsid with N-ethyl maleimide alters vector tissue tropism
Mulcrone, P. L., Lam, A. K., Frabutt, D. A., Zhang, J., Chrzanowski, M., Herzog, R. W., & Xiao, W. (2023) · Scientific Reports · doi:10.1038/s41598-023-35547-0 · Cited by 15
Non-canonical amino acid incorporation into AAV5 capsid enhances lung transduction in mice
Chang, H., Du, A., Jiang, J., Ren, L., Liu, N., Zhou, X., Liang, J., Gao, G., & Wang, D. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101129 · Cited by 14
Fluorescence Microscopy in Adeno-Associated Virus Research
Golm, S. K., Hübner, W., & Müller, K. M. (2023) · Viruses · doi:10.3390/v15051174 · Cited by 13
Structural characterization of an envelope-associated adeno-associated virus type 2 capsid
Hull, J. A., Mietzsch, M., Chipman, P. R., Strugatsky, D., & McKENNA, R. V. (2021) · Virology · doi:10.1016/j.virol.2021.09.010 · Cited by 13
Dai, Y., Dong, H., Gleason, C. R., Mora, J. R., Kolaitis, G., Balasubramanian, N., Surapaneni, S., Kozhich, A. T., & Jawa, V. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00805-6 · Cited by 12
“For example, there are 480 lysine residues exposed on the surface of AAV2 capsids that are amenable to chemical coupling (31).”
BackgroundUltrasound-enhanced gene transfection: vectors, methods, and biomedical applications
Wu, J., Gao, Y., Zhou, H., Yang, Z., Rodriguez, R. D. D., Xu, X., Ma, L., & Qiu, L. (2025) · Ultrasonics Sonochemistry · doi:10.1016/j.ultsonch.2025.107607 · Cited by 12
A facile chemical strategy to synthesize precise AAV-protein conjugates for targeted gene delivery
Pham, Q. T., Glicksman, J., Han, B., Shahraeini, S. S., Jewel, D., Loynd, C., Roy, S. J. S., & Chatterjee, A. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.201040 · Cited by 11
“Small retargeting ligands, such as short peptides and aptamers have been used for such proof-of-concept applications, 4,22–25 but the clinical utility of these approaches are limited by suboptimal affinity, selectivity, and in vivo stability of such ligands.”
Rational Design of AAV-rh74, AAV3B, and AAV8 with Limited Liver Targeting
Chan, C. T., Harris, K. K., Zolotukhin, S., & Keeler, G. D. (2023) · Viruses · doi:10.3390/v15112168 · Cited by 12
Imai, T., Miyai, M., Nemoto, J., Tamai, T., Ohta, M., Yagi, Y., Nakanishi, O., Mochizuki, H., & Nakamori, M. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adq2005 · Cited by 10
Zhao, W., Luo, J., Wang, F., Shi, Y., Zhang, J., Zhang, Y., Li, Y., Wang, X., Chen, Y., Zhang, X., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.015 · Cited by 10
Pinto, M. S.-L., Marti, L., Alarcón, J. F., Sitia, G., Fornaguera, C., Borrós, S., & Guerra‐Rebollo, M. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113896 · Cited by 8
Advances in designing Adeno-associated viral vectors for development of anti-HBV gene therapeutics
Mnyandu, N., Limani, S. W., Arbuthnot, P. B., & Maepa, M. B. (2021) · Virology Journal · doi:10.1186/s12985-021-01715-9 · Cited by 9
Gutiérrez-Guerrero, A., Perian, S., Leray, A., Martinello, C., Abrey-Recalde, M. J., Costa, C., Herrero, C. I., Bouzelha, M., Álvarez‐Dorta, D., Gouin, S. G., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102495 · Cited by 7
“26,27 We used both lysine and tyrosine here to introduce a ligand at the rAAV surface by click chemistry (Figure 2A).”
Self-citationGene editing in liver diseases
Torella, L., Santana‐Gonzalez, N., Zabaleta, N., & González‐Aseguinolaza, G. (2024) · FEBS Letters · doi:10.1002/1873-3468.14989 · Cited by 9
“One method involves linking ligands that bind to specific receptors on hepatocyte surfaces to the viral capsid, such as the chemical attachment of GalNAc [41,42].”
Sharifi, L., Ghasemi, J. B., Duran, T., Naik, S., DiLuzio, W. R., Sharifi, A. H., Chanda, A., & Chaudhuri, B. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125867 · Cited by 7
Yoo, S., Kang, B., Oh, S., Kim, Y., & Jang, J. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00351 · Cited by 6
Gene therapies for osteoarthritis: progress and prospects
Defois, A., Bon, N., Mével, M., Deniaud, D., Maugars, Y., Guicheux, J., Adjali, O., & Vinatier, C. S. (2024) · Journal of Cartilage & Joint Preservation · doi:10.1016/j.jcjp.2024.100186 · Cited by 6
Self-citationStructural basis for Rep-mediated adeno-associated virus packaging
Xu, V., McInnes, A., Wake, M., Acebrón-García-de-Eulate, M., Barritt, J. D., Bubeck, D., & Rouse, S. L. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117044 · Cited by 6
Research Status and Applications of Adeno‐Associated Virus
Xia, K., Liu, S., Wu, Z., & Jiang, J. (2024) · ChemBioChem · doi:10.1002/cbic.202400856 · Cited by 4
Xue, F., Sheng, R., Wang, Q., Wang, Y., Lei, K., Liu, Y., Yu, L., Tsukasaki, M., Ding, C., Li, J., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114326 · Cited by 5
Egorova, T. V., Piskunov, A. A., & Poteryaev, D. A. (2024) · Biological Products Prevention Diagnosis Treatment · doi:10.30895/2221-996x-2024-24-2-123-139 · Cited by 5
Lu, Y., Stoof, J., Tanoé, Y. R., Walsh, N., Bijlsma, M. F., Lei, H., Chen, T., Grahovac, J., Grützmann, R., & Pilarsky, C. P. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.07.004 · Cited by 3
Zheng, X., Wang, C., Zhang, Z., Wang, H., Gao, P., & Weng, L. (2025) · Biosensors · doi:10.3390/bios16010021 · Cited by 3
“…beyond food and biomedical sectors into gene therapy, where chemical modifications of viral capsids like adeno-associated virus (AAV) vectors are being explored to improve targeting and reduce immune responses, though challenges related to protein stoichiometry and vector fitness persist [221,222].”
Gene and cell-based therapies for retinal and optic nerve disease
Esposito, E. P., Han, I. C., & Johnson, T. V. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90120-8.00016-2 · Cited by 5
Stiles, K. M., Frenk, E. Z., Kaminsky, S. M., & Crystal, R. G. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.200 · Cited by 4
“Me´vel et al. 36 conjugated the N-acetylgalactosamine (GalNAc) ligand to the native lysines in the AAV2 capsid for hepatocyte-targeted delivery through the asialoglyco-protein and demonstrated significantly enhanced transduction of primary mouse hepatocytes and a modest increase in hepatocyte transduction in vivo .”
Advancing liver gene therapy: Enhanced transduction with GalNAc-bioconjugated rAAV capsids
Lalys, P.-A., Bourdon, A., Bouzelha, M., Álvarez‐Dorta, D., Pavageau, K., Girard, T., Peumery, R., Bouchouireb, Z., Marchand, M., Mellet, A., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118300 · Cited by 2
Self-citationArtemyev, V., Paremskaia, A. I., Dzhioeva, A. A., Mishina, D., Bogdanov, V. P., Krupinova, J. A., Mazloum, A., Feoktistova, S. G., Mityaeva, O. N., & Volchkov, P. (2025) · Cells · doi:10.3390/cells15010014 · Cited by 4
An Expanded Toolbox for Versatile Chemical Editing of Adeno‐Associated Virus
Pham, Q. T., Glicksman, J., Han, B., Koo, D., Loynd, C., Roy, S. J. S., & Chatterjee, A. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.202516157 · Cited by 2
Milagros, S., de Erenchun, P. R.-R., Guembe, M., Carte, B., Méndez, M., Uribarri, A., & Aldabe, R. (2024) · Journal of Biological Engineering · doi:10.1186/s13036-024-00430-7 · Cited by 4
“Interestingly, distinct outcomes are achieved when GalNac or Mannose is covalently linked to the AAV2 surface through the formation of a thiourea bond with the accessible amino groups or tyrosine bioconjugation of the rAAV capsid [23, 34, 35].”
BackgroundBioorthogonal Chemical Engineering of rAAV Capsid: Advancing Gene Therapy Targeting Using Proteins
Marchand, M., Depienne, S., Bouzelha, M., Pavageau, K., Peumery, R., Loquet, D., Álvarez‐Dorta, D., Guilbaud, M., Croyal, M., Dupont, A., et al. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00580 · Cited by 2
Self-citationJäschke, N. M., & Büning, H. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.04.002 · Cited by 2
Demontrond, F., Pascal, Y., Donnier‐Maréchal, M., Raillon, C., Luton, B., la Tramblais, C. D., Vial, L., Gueyrard, D., Galia, W., Berger, E., et al. (2024) · ChemRxiv · doi:10.26434/chemrxiv-2024-dfz7p · Cited by 2
Histidine‐Specific Bioconjugation: Expanding the Chemical Biology Toolbox for Protein Modification
Bandyopadhyay, A., & Sarkar, R. (2026) · ChemistrySelect · doi:10.1002/slct.73926 · Cited by 1
Milagros, S., de Erenchun, P. R.-R., Guembe, M., Carte, B., Mendez, M., Uribarri, A., & Aldabe, R. (2024) · Research Square · doi:10.21203/rs.3.rs-3848603/v1 · Cited by 1
Adeno-associated viruses escort nanomaterials to specific cells and tissuesPreprint
Nagao, K., Paniagua, E. V., Lei, K., Beckham, J. L., Worthington, P., Manthey, M., Ye, M., Koehler, F., Kim, Y. J., Malkin, E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.04.647267 · Cited by 2
Design and construction of bioinspired supramolecular self-assembled nanostructures
Plascencia‐Villa, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90984-6.00017-9
Characterization of Adeno-Associated Virus (AAV) Gene Therapy Products
Rathore, A. S., Auclair, J. R., & Kaur, A. (2023) · LCGC North America · doi:10.56530/lcgc.na.st3379l8
AAV-Vektoren – die imposante Karriere eines Parvovirus
Jäschke, N. M., & Büning, H. (2023) · Springer eBooks · doi:10.1007/978-3-662-67908-1_4
Depienne, S., Deniaud, D., Mével, M., & Gouin, S. G. (2024) · médecine/sciences · doi:10.1051/medsci/2024103
Self-citationEnhancing Adeno‐Associated Virus 2 Capsid Engineering Through Co‐Evolutionary Coupling
Laosinwattana, S., Li, Y., Sanchez, B. C., Khan, A., & Dalby, P. A. (2026) · Biotechnology and Bioengineering · doi:10.1002/bit.70349
Demontrond, F., Pascal, Y., Donnier‐Maréchal, M., Raillon, C., Luton, B., la Tramblais, C. D., Vial, L., Gueyrard, D., Galia, W., Berger, E., et al. (2025) · Chemistry - A European Journal · doi:10.1002/chem.202502161 · Cited by 2
Milagros, S., de Erenchun, P. R.-R., Guembe, M., Carte, B., Méndez, M., Uribarri, A., & Aldabe, R. (2024) · Figshare · doi:10.6084/m9.figshare.25824759
An Expanded Toolbox for Versatile Chemical Editing of Adeno‐Associated Virus
Pham, Q. T., Glicksman, J., Han, B., Koo, D., Loynd, C., Roy, S. J. S., & Chatterjee, A. (2026) · Angewandte Chemie · doi:10.1002/ange.202516157
Modification chimique d’AAV pour la thérapie génique
Leray, A. (2021) · theses.fr (ABES) · doi:10.70675/c33b1ba2z6c22z40e1z9a98z3ed26b698b7a
Self-citationLehot, V. (2021) · theses.fr (ABES) · doi:10.70675/718d38b9z5733z42a0z857azc52585ec3dbc
Terras, F. (2020) · theses.fr (ABES) · doi:10.70675/872df6d1ze1b9z4a8dzb02dzad4656ff10f0 · Cited by 1
Journou, M. (2021) · theses.fr (ABES) · doi:10.70675/9a618ac2za0a4z4e90zbdb3ze14482ffa655
Nouvelle génération d’AAV : un mélange de chimie organique et de vectorologie
Lalys, P.-A. (2023) · theses.fr (ABES) · doi:10.70675/b6df86c2z6520z473ez9e10ze1740b9bc3ae
Luo, J., Shi, Y., Ji, D., Jiao, P., Wang, F., Zhang, J., Wang, X., Wang, Y., Chen, Z., Yu, M., et al. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124381 · Cited by 1
Site-Specific Chemical Conjugation of Recombinant Proteins onto the AAV Capsid
Pham, Q. T., Glicksman, J., & Chatterjee, A. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5112-4_1
Milagros, S., Pérez‐Martínez, D., Salazar-Diaz, S., de Erenchun, P. R.-R., Nicolao, M., Carte, B., Méndez, M., Echevarria, B., Reichardt, N., & Aldabe, R. (2026) · Research Square · doi:10.21203/rs.3.rs-10369568/v1
Controllable gene delivery via masked adeno-associated viral vectors
Zeng, Z., Chang, L., Wang, J., Liu, Y., Wang, X., Sun, Y., Zuo, Y., Xiaoyu, H., Wang, Y., Gu, Z., et al. (2026) · Nature Materials · doi:10.1038/s41563-026-02724-1 · Cited by 1
Metadata
- Authors
- Mével, M., Bouzelha, M., Leray, A., Pacouret, S., Guilbaud, M., Penaud-Budloo, M., Alvarez-Dorta, D., Dubreil, L., Gouin, S. G., Combal, J. P., Hommel, M., Gonzalez-Aseguinolaza, G., Blouin, V., Moullier, P., Adjali, O., Deniaud, D., & Ayuso, E.
- Affiliations
- Inserm (FR)
- INSERM UMR 1089
- LUNAM Université
- Oniris (FR)
- Centre National de la Recherche Scientifique (FR)
- Vivet Therapeutics SAS
- Navarre Institute of Health Research (ES)
- Corresponding author
- Mével, Mathieu
- Deniaud, David
- Ayuso, Eduard
- ORCID
- Venue
- Chemical Science
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2020
- Volume
- 11
- Issue
- 4
- Pages
- 1122-1131
- ISSN
- 2041-6520 (ISSN-L)
- 2041-6539
- PMC
- PMC8145868
- OpenAlex
- W2993926737
- Cited by
- 92
- References
- 40
- Citations by year
- 2026: 9 · 2025: 19 · 2024: 20 · 2023: 17 · 2022: 9 · 2021: 13 · 2020: 5
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Chemical Science (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Deposito Adademico Digital Universidad De Navarra (University of Navarra) (submittedVersion, cc-by-nc)
- HAL (submittedVersion, other-oa)
- Funders
- Institut National de la Santé et de la Recherche Médicale
- Université de Nantes
- Centre Hospitalier Universitaire de Nantes
- Agence Nationale de la Recherche (ANR-11-EQPX-0004)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- adeno-associated virus, AAV capsid, chemical modification, bioconjugation, gene delivery, ligand coupling, cell tropism, neutralizing antibodies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.